Capivasertib vs Inavolisib: Comparing PI3K-AKT Pathway Targeted Therapies in HR+/HER2− Breast Cancer
With the development of precision medicine, the treatment model for HR+/HER2− breast cancer is evolving rapidly.
From traditional endocrine therapy, to the widespread use of CDK4/6 inhibitors, and now to the emergence of targeted drugs aimed at the PI3K-AKT-mTOR signaling pathway, the treatment landscape is undergoing significant transformation.
As a global pharmaceutical distributor focused on anticancer drug supply and clinical developments, DengYueMed has observed that therapies targeting the PI3K-AKT pathway are becoming an increasingly important direction in precision treatment for HR-positive breast cancer.
Two targeted therapies that have attracted significant attention in recent years — Capivasertib and Inavolisib — provide new treatment options for patients with endocrine-resistant disease and were approved for marketing in China in 2025.
By targeting different key nodes within the same signaling pathway, these two drugs offer new precision treatment strategies for patients with HR+/HER2− breast cancer.
The Role of the PI3K-AKT Signaling Pathway in Breast Cancer
The PI3K-AKT-mTOR signaling pathway is a critical molecular network regulating:
- cell growth
- metabolism
- survival
In many types of tumors, abnormal activation of this pathway is closely associated with tumor development and progression.
Among patients with HR+ breast cancer, several molecular alterations are relatively common:
- PIK3CA mutations
- AKT1 mutations
- PTEN loss
These alterations can lead to persistent activation of the signaling pathway, allowing tumor cells to continuously receive growth signals and potentially reduce the effectiveness of endocrine therapy and CDK4/6 inhibitors.
Therefore, directly targeting the PI3K-AKT pathway has become one of the key strategies in precision breast cancer therapy.
Capivasertib: A New-Generation AKT Inhibition Strategy
Capivasertib is an oral AKT kinase inhibitor that suppresses tumor cell proliferation and survival by blocking AKT signal transduction.
AKT is located at the central node of the PI3K signaling pathway. Its activation promotes:
- cellular metabolism
- cell-cycle progression
- anti-apoptotic signaling
By inhibiting AKT activity, Capivasertib interferes with tumor growth mechanisms at the molecular level.
In the treatment of HR+/HER2− breast cancer, the drug is typically used in combination with endocrine therapy to enhance antitumor effects and delay disease progression.
One important feature of AKT inhibitors is their ability to function across multiple upstream mutation backgrounds, including:
- PIK3CA mutations
- AKT1 mutations
- PTEN alterations
Therefore, their potential target population may be relatively broad.
Inavolisib: A Precision Strategy Targeting PI3Kα
In contrast, Inavolisib is a selective PI3Kα inhibitor designed primarily for tumors driven by PIK3CA mutations.
PIK3CA is one of the most common driver mutations in HR+ breast cancer. Mutations in this gene can lead to persistent activation of PI3K signaling, promoting tumor cell growth and survival.
By inhibiting the PI3Kα isoform, Inavolisib can:
- block upstream activation of the signaling pathway
- suppress tumor cell proliferation
Because of its highly targeted mechanism, PI3Kα inhibitors are generally used in patients with confirmed PIK3CA mutations based on genetic testing in order to achieve better therapeutic outcomes.
Mechanistic Differences Between Capivasertib and Inavolisib
Although both drugs belong to PI3K-AKT pathway targeted therapies, they act at different positions within the signaling pathway.
The pathway can be simplified as:
PI3K → AKT → mTOR
Therefore:
- Inavolisib acts on the upstream PI3K node
- Capivasertib acts on the downstream AKT node
These mechanistic differences mean that the two drugs may differ in target patient populations and treatment strategies.
| Dimension | Capivasertib | Inavolisib |
|---|---|---|
| Drug type | AKT inhibitor | PI3Kα inhibitor |
| Target | AKT1 / AKT2 / AKT3 | PI3Kα |
| Target population | Patients with AKT pathway abnormalities | Patients with PIK3CA mutations |
| Typical regimen | + Fulvestrant | + Palbociclib + Fulvestrant |
| Key clinical trial | CAPItello-291 | INAVO120 |
| Treatment stage | Post-CDK4/6 therapy | First-line or early therapy |
Overall:
- Capivasertib may serve a broader patient population
- Inavolisib provides a more precise mutation-driven treatment strategy
Future Trends in Precision Oncology
The emergence of Capivasertib and Inavolisib reflects the broader shift in oncology toward mechanism-based precision medicine.
Several key trends may shape the future of breast cancer treatment:
1. More refined molecular classification
Genetic testing will increasingly guide therapy selection for individual patients.
2. Multi-pathway combination therapy
Targeting multiple signaling pathways simultaneously may help delay or overcome drug resistance.
3. Personalized treatment strategies
Treatment pathways will increasingly depend on a patient’s molecular profile and disease progression.
With continued advances in molecular diagnostics and targeted drug development, therapies targeting the PI3K-AKT pathway are expected to play an increasingly important role in breast cancer management.
Conclusion
As important representatives of PI3K-AKT pathway targeted therapy, Capivasertib and Inavolisib highlight the potential of different molecular targeting strategies in precision oncology.
- Capivasertib provides a new option for patients with endocrine-resistant disease by inhibiting AKT signaling.
- Inavolisib offers a mutation-specific therapy for patients with PIK3CA-driven tumors.
DengYueMed will continue tracking cutting-edge developments in breast cancer, lung cancer, and rare disease therapeutics, providing reliable drug information resources for healthcare professionals and global medical partners.
For more oncology regulatory updates and new drug approvals, visit: